HomeStock ListAstraZeneca PLC

AstraZeneca PLC

Closed

Sector Healthcare

10,886 -1.04

Overview

Share price change

24h

Current

Min

10828

Max

11000

Key metrics

By Trading Economics

Income

-444M

1.4B

Sales

532M

12B

P/E

Sector Avg

34.276

23.904

EPS

1.45

Dividend yield

2.121

Profit margin

11.956

EBITDA

-412M

3.4B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

-6.11 downside

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.12%

7.76%

Next Earnings

25 Apr 2024

Market Stats

By TradingEconomics

Market Cap

4.4B

169B

Previous open

10887.04

Previous close

10886

News Sentiment

By Acuity

29%

71%

57 / 274 Healthcare

AstraZeneca PLC Chart

Related News

19 Mar 2024, 13:58 UTC

Acquisitions, Mergers, Takeovers

Trending: Astrazeneca Aims to Accelerate Cancer Treatment Development With $2.4 Billion Fusion Deal

19 Mar 2024, 10:18 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

Fusion Pharmaceuticals Shares Soar Premarket on AstraZeneca Deal

19 Mar 2024, 07:58 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca Buys Fusion for Up to $2.4 Billion -- Update

19 Mar 2024, 07:23 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca Buys Fusion for Initial $2 Billion

14 Mar 2024, 10:22 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca to Buy Rare-Disease Specialist Amolyt Pharma for Up to $1.05 Billion -- Update

14 Mar 2024, 07:32 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca to Buy Amolyt Pharma for Up to $1.05 Billion

11 Apr 2024, 09:12 UTC

Market Talk

AstraZeneca's CEO Pay Raises Compensation Questions Across Sector -- Market Talk

19 Mar 2024, 20:03 UTC

Acquisitions, Mergers, Takeovers

Fusion Rockets 97%, As Radiopharmaceuticals Space Sparks On $2 Billion AstraZeneca Takeover -- IBD

19 Mar 2024, 15:18 UTC

Market Talk
Acquisitions, Mergers, Takeovers

No Competing Bids Seen For Fusion Pharma -- Market Talk

19 Mar 2024, 15:00 UTC

Acquisitions, Mergers, Takeovers

Fusion Rockets 97%, As Radiopharmaceuticals Space Sparks On $2 Billion AstraZeneca Takeover -- IBD

19 Mar 2024, 13:03 UTC

Acquisitions, Mergers, Takeovers

Fusion Pharma Stock Nearly Doubles After Scoring $2 Billion AstraZeneca Takeover -- IBD

19 Mar 2024, 11:21 UTC

Acquisitions, Mergers, Takeovers

Fusion Pharmaceuticals Is Being Acquired by AstraZeneca in $2.4 Billion Deal. The Stock Is Soaring. -- Barrons.com

19 Mar 2024, 11:00 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca To Acquire Fusion To Accelerate The Development Of Next-generation Radioconjugates To Treat Cancer >AZN

19 Mar 2024, 09:33 UTC

Hot Stocks

Stocks to Watch Tuesday: Unilever, Fusion Pharmaceuticals, Tesla -- WSJ

19 Mar 2024, 07:43 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca Buys Fusion for Up to $2.4 Bln -- Update

19 Mar 2024, 07:08 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca Buys Fusion for Initial $2 Bln

19 Mar 2024, 07:03 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca: Initial Sum Values Fusion at $2bn

19 Mar 2024, 07:02 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca Buying Fusion for $21.00 a Shr, Plus Contingent Value Right of $3.00

19 Mar 2024, 07:01 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca Buying Fusion to Accelerate Development of Next-Generation Radioconjugates to Treat Cancer

19 Mar 2024, 07:00 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca to Buy Fusion

14 Mar 2024, 10:07 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca to Buy Rare-Disease Specialist Amolyt Pharma for Up to $1.05 Bln -- Update

14 Mar 2024, 07:17 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca to Buy Amolyt Pharma for Up to $1.05 Bln

14 Mar 2024, 07:03 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca: Transaction Is Expected to Close by the End of the 3Q of 2024

14 Mar 2024, 07:03 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca: To Buy All Shares of Amolyt Pharma For Up to $1.05B

14 Mar 2024, 07:01 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca: Amolyt's Development Portfolio Includes Phase III Asset Related to Chronic Hypoparathyroidism

14 Mar 2024, 07:00 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca PLC to Buy Amolyt

22 Feb 2024, 13:19 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca: Deal Was Announced in December 2023

22 Feb 2024, 13:17 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca: Acquisition Boosts Pipeline of Cell Therapy

22 Feb 2024, 13:16 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca: Gracell Biotechnologies Inc. is a Clinical-Stage Biopharmaceutical Developing Treatment of Cancer and Autoimmune Diseases

22 Feb 2024, 13:15 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca Completes Acquisition of Gracell

AstraZeneca PLC forecast

Price Target

By TipRanks

-6.11% downside

12 Months Forecast

Average 10,388.21 GBX  -6.11%

High 14,500 GBX

Low 120 GBX

Based on 17 Wall Street analysts offering 12 month price targets forAstraZeneca PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

17 ratings

12

Buy

3

Hold

2

Sell

Sentiment

By Acuity

57 / 274 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

$

About AstraZeneca PLC

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.